dbACP: A Comprehensive Database of Anti-Cancer Peptides

21 result(s) have been found!

Accession Name Sequence Source/Organism Mechanism Assay Type Cell Line Cancer Type Activity
dbacp02181 C7A-D21K KILRGVAKKIMRTFLRRISKKILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 8.4 ± 0.2 µM
dbacp02182 C7A-D21K KILRGVAKKIMRTFLRRISKKILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 12.3 ± 2.0 µM
dbacp02183 C7A-D21K KILRGVAKKIMRTFLRRISKKILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 8.3 ± 0.5 µM
dbacp02184 C7A-D21K KILRGVAKKIMRTFLRRISKKILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 12.3 ± 1.0 µM
dbacp02185 C7A-D21k KILRGVAKKIMRTFLRRISKKILTGKK NK-2 variants Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 8.4 ± 0.2 µM
dbacp02186 C7A-D21k KILRGVAKKIMRTFLRRISKKILTGKK NK-2 variants Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 12.3 ± 2.0 µM
dbacp02187 C7A-D21k KILRGVAKKIMRTFLRRISKKILTGKK NK-2 variants Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 8.3 ± 0.5 µM
dbacp02188 C7A-D21k KILRGVAKKIMRTFLRRISKKILTGKK NK-2 variants Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 12.3 ± 1.0 µM
dbacp02189 C7A-D21K KILRGVAKKIMRTFLRRISKKILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HCT-116 Colorectal cancer Cell viability : 50% at 12.5μM approx.
dbacp02190 C7A-D21K KILRGVAKKIMRTFLRRISKKILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC24 Colorectal cancer Cell viability : >50% at 25μM approx.
dbacp02191 C7A-D21K KILRGVAKKIMRTFLRRISKKILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC40 Colorectal cancer Cell viability : >50% at 25μM approx..
dbacp02192 C7A-D21K KILRGVAKKIMRTFLRRISKKILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC60 Colorectal cancer Cell viability : >50% at 25μM approx.
dbacp02193 C7A-D21K KILRGVAKKIMRTFLRRISKKILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC32 Colorectal cancer Cell viability : 50% at 12.5μM approx.
dbacp02194 C7A-D21K KILRGVAKKIMRTFLRRISKKILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HCT-116 Colorectal cancer Cell viability : >40% at 12.5μM approx.
dbacp02195 C7A-D21K KILRGVAKKIMRTFLRRISKKILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC18 Colorectal cancer Cell viability : >55% at 12.5μM approx.
dbacp02196 C7A-D21K KILRGVAKKIMRTFLRRISKKILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC24 Colorectal cancer Cell viability : >55% at 12.5μM approx.
dbacp02197 C7A-D21K KILRGVAKKIMRTFLRRISKKILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC40 Colorectal cancer Cell viability : >80% at 12.5μM approx.
dbacp02198 C7A-D21K KILRGVAKKIMRTFLRRISKKILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC60 Colorectal cancer Cell viability : >60% at 12.5μM approx.
dbacp02199 C7A-D21K KILRGVAKKIMRTFLRRISKKILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC113 Colorectal cancer Cell viability : >65% at 12.5μM approx.
dbacp02200 C7A-D21K KILRGVAKKIMRTFLRRISKKILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC32 Colorectal cancer Cell viability : >80% at 12.5μM approx.
dbacp02201 C7A-D21K KILRGVAKKIMRTFLRRISKKILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC107 Colorectal cancer Cell viability : >65% at 12.5μM approx.